U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C14H17NO2
Molecular Weight 231.2903
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BENZOCLIDINE

SMILES

O=C(OC1CN2CCC1CC2)C3=CC=CC=C3

InChI

InChIKey=AHKAOMZZTQULDS-UHFFFAOYSA-N
InChI=1S/C14H17NO2/c16-14(12-4-2-1-3-5-12)17-13-10-15-8-6-11(13)7-9-15/h1-5,11,13H,6-10H2

HIDE SMILES / InChI

Description

Benzoclidine (Oxylidin) exerts tranquilizing and hypotensive actions. It reduces the excitability of the central nervous system, enhances the effect of hypnotic drugs, analgesics and local anesthetics, has a moderate antihypertensive effect, reduces the excitability of the vasomotor centers, has anti-arrhythmic activity. Benzoclidine is marke indicated for the treatment of anxiety and depression of various origins (particularly mild expressed and associated with cerebrovascular insufficiency), neurosis, personality disorder, cyclothymia, hypertension with cerebral disorders, sinus tachycardia, paroxysmal tachycardia.

CNS Activity

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Benzoclidine
Primary
Benzoclidine
Primary
Benzoclidine

PubMed

Sample Use Guides

In Vivo Use Guide
Average therapeutic dose oral, subcutaneous and intramuscular injection 0.02 - 0.3 grams daily, the duration of treatment 3-8 weeks.
Route of Administration: Other
In Vitro Use Guide
Unknown